ArborGen files registration statement with Securities and Exchange Commission

NewsGuard 100/100 Score

ArborGen Inc., the world's leading developer of biotechnology tree seedling products and one of the largest providers of conventional and technology-enhanced seedlings to the global commercial forestry industry, announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Goldman, Sachs & Co. and Citi will act as joint book-runners for the proposed offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. When available, a preliminary prospectus relating to the proposed offering may be obtained from either: Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or email: [email protected]; or Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, 8th Floor Brooklyn, NY 11220, telephone: 800-831-9146, or email: [email protected].

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Longitudinal multi-omics monitoring paves the way for early pancreatic cancer diagnosis